ZL-1503 / ZAI Lab - LARVOL DELTA

ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates (EAACI 2025) - No abstract available

Immunology

Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates (Businesswire) - "ZL-1102 (IL-17 Humabody): Zai Lab to provide interim analysis in the global Phase 2 study in chronic plaque psoriasis in the first half of 2025. ZL-1503 (IL-13/IL-31R): Zai Lab to provide preclinical data update and initiate a global Phase 1 study in moderate-to-severe atopic dermatitis...Seronegative gMG: Zai Lab partner argenx to provide topline results from the Phase 3 ADAPT-SERON study in seronegative gMG. Zai Lab participated in the study in Greater China. Lupus Nephritis (LN): Zai Lab to provide topline results from the Phase 2 study in LN."

New P1 trial • P2 data • P3 data • Preclinical • Atopic Dermatitis • Lupus Nephritis • Myasthenia Gravis • Psoriasis

ZL-1503, a Bispecific, Serum Half-life Extended Antibody Targeting Both Inflammatory and Pruritogenic Pathways for Atopic Dermatitis and Other IL-13/IL-31 Related Diseases (EADV 2024) - No abstract available

Late-breaking abstract • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13

ZL-1503, a bispecific, serum half-life extended antibody targeting both inflammatory and pruritogenic pathways for atopic dermatitis and other IL-13/IL-31 related diseases (EADV 2024) - No abstract available

Late-breaking abstract • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13